ACM
ANRO icon

Accent Capital Management’s Alto Neuroscience ANRO Stock Holding History

Accent Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.66K Buy
366
+91
+33% +$2.1K ﹤0.01% 223
2026
Q1 		$6.18K Buy
+275
New +$5.1K ﹤0.01% 257

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Accent Capital Management's ANRO Position: Q2 2026 in Review

Accent Capital Management increased its Alto Neuroscience (ANRO) stake by 33% in Q2 2026, buying an estimated $2.1K and bringing the position to 366 shares worth $9.66K. The position accounts for ﹤0.01% of the portfolio, ranked #223.

Accent Capital Management first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Accent Capital Management held 366 shares of Alto Neuroscience worth $9.66K as of Q2 2026.
  • Accent Capital Management bought 91 Alto Neuroscience shares in Q2 2026, an estimated $2.1K.
  • Alto Neuroscience made up ﹤0.01% of Accent Capital Management's portfolio in Q2 2026, its #223 holding.
  • Accent Capital Management first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.